Pacific Biosciences of California Inc (PACB) Stock Analysis
Verdict: AVOID
Contract momentum masks severe debt ($759.9M) and cash burn (<7 months runway), pointing to high dilution risk.
Investment score: 31/100
Analysis as of
Is Pacific Biosciences of California Inc stock worth reviewing? The TradeMates thesis
The model assesses PACB as an AVOID due to severe solvency risk, negative cash runway (<7 months), and a market price 100.8% above consensus target ($1.18).
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Pacific Biosciences of California Inc opportunities and risks
What speaks for PACB
- Consumable stream expansion from new commercial wins
What speaks against PACB
- Critical cash runway limit under 7 months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PACB | n/a | 4.6x | n/a | 36.0% | -82.5% | -23.3% |
| PSNL | n/a | 24.9x | n/a | 12.7% | -153.8% | -5.8% |
| AZTA | n/a | 2.6x | n/a | 44.0% | -20.0% | 0.6% |
| CYRX | n/a | 4.7x | n/a | 47.1% | -19.5% | -2.3% |
| DNA | n/a | 7.5x | n/a | 80.1% | -260.0% | -22.7% |
| CTKB | n/a | 3.7x | n/a | 53.2% | -39.0% | -1.6% |
| Peer median | n/a | 4.7x | n/a | 47.1% | -39.0% | -2.3% |
Frequently asked questions about Pacific Biosciences of California Inc (PACB)
Is PACB stock a good investment?
The TradeMates model rates Pacific Biosciences of California Inc as AVOID with an investment score of 31/100. The model assesses PACB as an AVOID due to severe solvency risk, negative cash runway (<7 months), and a market price 100.8% above consensus target ($1.18). This is algorithmic model output, not personal investment advice.
Is PACB stock a buy?
The TradeMates model verdict for PACB is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.